SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

July 13, 2017 12:31 ET

CTD Holdings to Present at 25th Annual Family Conference of the National Niemann-Pick Disease Foundation

Event Brings Together Families and Niemann-Pick Disease Type C Patient Advocates from the U.S. and Internationally

ALACHUA, FL--(Marketwired - July 13, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the 25th Annual Family Conference of the National Niemann-Pick Disease Foundation. The conference will take place at the Hilton Rosemont/Chicago O'Hare Hotel, Chicago, IL, from August 10 through August 13, 2017.

CTD's presentation will focus on the U.S. Phase I clinical trial of Trappsol® Cyclo™, its proprietary formulation of hydroxypropyl beta cyclodextrin, for the treatment of Niemann-Pick Disease Type C (NPC). The U.S. trial is currently recruiting patients. The presentation will also include data from CTD's compassionate use program with Trappsol® Cyclo™, which began in 2009. The presentation will be made by Dr. Caroline Hastings, Principal Investigator, and Dr. Benny Liu, Co-Investigator, of the Phase I trial. Dr. Hastings was the first physician in the U.S. to provide cyclodextrins in the form of Trappsol® Cyclo™ on a compassionate use basis to NPC patients, and Dr. Liu was the first researcher to demonstrate the efficacy of cyclodextrins in an animal model of NPC disease.

The conference brings together patients, families and care givers for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support.

Presentation Details:

Date: Friday, August 11th

Time: Afternoon Session

Location: Hilton Rosemount/Chicago O'Hare Hotel, Chicago, Il

Dr. Sharon Hrynkow, CTD's Senior Vice President for Medical Affairs, will introduce CTD's Family and Patient Liaisons, Ms. Shannon Reedy of the U.S. and Ms. Jackie Imrie of the UK. The company encourages families and NPC patients interested in the clinical trial to contact Ms. Reedy ( or Ms. Imrie ( or to visit with them and the CTD team at the conference.

About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company's website:

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information